Literature DB >> 7341283

Differential induction of antipyrine metabolism by rifampicin.

E L Toverud, A R Boobis, M J Brodie, S Murray, P N Bennett, V Whitmarsh, D S Davies.   

Abstract

Antipyrine is oxidised to three main metabolites in man. There is evidence that the different metabolites are products of different forms of cytochrome P-450. The effect of rifampicin administration for two weeks on the rates of formation of these metabolites was investigated in healthy volunteers. Rifampicin increased antipyrine clearance and shortened its half-life. Two weeks after stopping rifampicin the induction had largely been reversed. Clearance to all three metabolites was increased by rifampicin. Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min. Thus clearance to norphenazone was increased to a much greater extent than to either of the other two metabolites. It is concluded that this provides evidence for the involvement of at least two different forms of cytochrome P-450 in antipyrine metabolism in man.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7341283     DOI: 10.1007/bf00637517

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  The effect of spironolactone on antipyrine metabolism in man.

Authors:  D H Huffman; D W Shoeman; P Pentikäinen; D L Azarnoff
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

3.  Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.

Authors:  P B Andreasen; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

4.  Influence of inducers and inhibitors on the hydroxylation pattern of N-hexane in rat liver microsomes.

Authors:  U Frommer; V Ullrich; S Orrenius
Journal:  FEBS Lett       Date:  1974-04-15       Impact factor: 4.124

5.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

6.  Regioselective and stereoselective hydroxylation of R and S warfarin by different forms of purified cytochrome P-450 from rabbit liver.

Authors:  M J Fasco; K P Vatsis; L S Kaminsky; M J Coon
Journal:  J Biol Chem       Date:  1978-11-10       Impact factor: 5.157

7.  Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.

Authors:  M Danhof; D P Krom; D D Breimer
Journal:  Xenobiotica       Date:  1979-11       Impact factor: 1.908

8.  4,4'-Dihydroxyphenazone as an urinary metabolite of phenazone in different species including man.

Authors:  H Bässmann; J Böttcher; R Schüppel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-11       Impact factor: 3.000

9.  Induction of hepatic microsomal enzymes after brief administration of rifampicin in man.

Authors:  J P Miguet; P Mavier; C J Soussy; D Dhumeaux
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

10.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors:  M Danhof; E de Groot-van der Vis; D D Breimer
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

View more
  33 in total

1.  Metabolism of the aldose reductase inhibitor ALO1567 in man.

Authors:  Y H Park; J E Hudson; R C Barker; B M York; R K Brazzell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.

Authors:  E Perucca; R Grimaldi; G M Frigo; A Sardi; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Plasma antipyrine half-life can be determined from urine data.

Authors:  J O Atiba; G Taylor; R A Pershe; T F Blaschke
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

5.  Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.

Authors:  D Vital Durand; C Hampden; A R Boobis; B K Park; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

Review 6.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

7.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 8.  Sex-related differences in drug disposition in man.

Authors:  K Wilson
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

Review 9.  Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.

Authors:  M Døssing
Journal:  Int Arch Occup Environ Health       Date:  1984       Impact factor: 3.015

10.  Hepatic microsomal enzyme function in technicians and anesthesiologists exposed to halothane and nitrous oxide.

Authors:  M Døssing; P Weihe
Journal:  Int Arch Occup Environ Health       Date:  1982       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.